Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2022 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting

NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
November 21, 2022 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data

Early data from the first two patients treated with NRTX-1001 report a trend toward seizure suppression and that administration of the cell treatment has been well-tolerated thus far Pioneering cell...
September 21, 2022 12:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears advancement of...
June 29, 2022 07:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy Pioneering cell therapy approach could revolutionize the treatment of...
June 17, 2022 16:55 ET | Source: Neurona Therapeutics

Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting

Oral presentation will outline design of first ever Phase 1/2 clinical trial of regenerative human cell therapy in epilepsy Presentations will detail single-cell transcriptomic profiling of NRTX-1001...
May 26, 2022 16:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy

CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate...
April 04, 2022 16:01 ET | Source: Neurona Therapeutics

Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today...
April 01, 2022 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy

SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
January 05, 2022 16:02 ET | Source: Neurona Therapeutics

Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...
December 13, 2021 08:00 ET | Source: Neurona Therapeutics

Neurona Therapeutics Announces C-Suite Leadership Team

SAN FRANCISCO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...